{"preliminary_commentary":{"by_channel":{"x_thread":97,"youtube":32,"podcast":31,"x_video":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT03012321\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"name":"PCCTC #: c16-168","nct_id":"NCT03012321","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=pcctc-c16-168-nct03012321. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1950,"size":"deep","size_rule":"Deep: 301+ verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Abiraterone 1000 mg orally once daily and prednisone 5 mg orally twice daily, days 1-28 in 28 day cycles.","label":"Arm I: Abiraterone + Prednisone","type":"ACTIVE_COMPARATOR"},{"description":"Olaparib 300 mg orally twice daily for days 1-28 in 28 day cycles.","label":"Arm II: Olaparib","type":"ACTIVE_COMPARATOR"},{"description":"Abiraterone 1000 mg orally once daily, prednisone 5 mg orally twice daily, olaparib 300 mg orally twice daily for days 1-28 in 28 day cycles.","label":"Arm III: Abiraterone + Prednisone + Olaparib","type":"ACTIVE_COMPARATOR"},{"description":"Olaparib 300 mg orally twice daily for days 1-28 in 28 day cycles.","label":"Olaparib","type":"ACTIVE_COMPARATOR"}],"collaborators":["AstraZeneca","National Cancer Institute (NCI)"],"completion_date":{"date":"2027-01-16","type":"ESTIMATED"},"conditions":["Prostate Cancer Metastatic Castration-Resistant","Abnormal DNA Repair","Metastatic Prostate Carcinoma","Stage IV Prostate Cancer"],"enrollment":{"count":70,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Olaparib","otherNames":["Lynparza"],"type":"DRUG"},{"name":"Abiraterone Acetate","otherNames":[],"type":"DRUG"},{"name":"Prednisone","otherNames":[],"type":"DRUG"}],"last_update":"2026-06-01","lead_sponsor":"Northwestern University","official_title":"BRCAAway: A Randomized Phase II Trial of Abiraterone, Olaparib, or Abiraterone + Olaparib in Patients With Metastatic Castration-Resistant Prostate Cancer With DNA Repair Defects","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE2"],"primary_completion_date":{"date":"2023-10-21","type":"ACTUAL"},"primary_outcomes":[{"measure":"Objective Progression Free Survival (PFS)","timeFrame":"Up to 2 years"}],"references":[{"citation":"Collins K, Cheng L. Reprint of: morphologic spectrum of treatment-related changes in prostate tissue and prostate cancer: an updated review. Hum Pathol. 2023 Mar;133:92-101. doi: 10.1016/j.humpath.2023.02.007. Epub 2023 Mar 8.","pmid":"36898948","type":"DERIVED"}],"start_date":{"date":"2017-01-12","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Abiraterone/Prednisone, Olaparib, or Abiraterone/Prednisone + Olaparib in Patients With Metastatic Castration-Resistant Prostate Cancer With DNA Repair Defects","url":"https://clinicaltrials.gov/study/NCT03012321"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/pcctc-c16-168-nct03012321"}